Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
US11608383B2 · kind B2 · utility
2Cited by
13References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2021 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | Dec 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.